Role of Fibroblasts in the Subtype Specific Therapeutic Effects of Nintedanib in Non-Small Cell Lung Cancer (NSCLC)

被引：0
|
作者：
Gabasa, Marta [1 ]
Ikemori, Rafael [1 ]
Solca, Flavio [2 ]
Hilberg, Frank [2 ]
Reguart, Noemi [3 ]
Alcaraz, Jordi [1 ]
机构：
[1] Univ Barcelona, Dept Biomed, Fac Med, Barcelona, Spain
[2] Boehringer Ingelheim Rcv GmbH & Co Kg, Vienna, Austria
[3] Hosp Clin Barcelona, Barcelona, Spain
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
nintedanib; TGF-beta; tumor microenvironment; cancer associated fibroblasts;
D O I：
10.1016/j.jtho.2016.11.292
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA11.06
引用
收藏
页码：S287 / S288
页数：2
相关论文
共 50 条
  • [21] Functional Role of Cancer Associated Fibroblasts in Non-Small Cell Lung Cancer Patients
    Navab, Roya
    Hao, Jing
    Pintilier, Melania
    Wang, Tao
    Jurisica, Igor
    Tsao, Ming S.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S393 - S393
  • [22] Antiangiogenic-specific adverse events (AEs) in patients with non-small cell lung cancer (NSCLC) treated with nintedanib (N) and docetaxel (D).
    Reck, Martin
    Mellemgaard, Anders
    Orlov, Sergey V.
    Krzakowski, Maciej Jerzy
    Von Pawel, Joachim
    Gottfried, Maya
    Bondarenko, Igor
    Liao, Mei-Lin
    Barrueco, Jose
    Hocke, Julia
    Kaiser, Rolf
    Novello, Silvia
    Douillard, Jean-Yves
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [23] ANTIANGIOGENIC-SPECIFIC ADVERSE EVENTS (AES) IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH NINTEDANIB (N) AND DOCETAXEL (D)
    Mellemgaard, Anders
    Reck, Martin
    Orlov, Sergey
    Krzakowski, Maciej
    Von Pawel, Joachim
    Gottfried, Maya
    Bondarenko, Igor
    Liao, Meilin
    Barrueco, Jose
    Hocke, Julia
    Aboshady, Hesham
    Novello, Silvia
    Douillard, Jean-Yves
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (09) : S155 - S155
  • [24] Atezolizumab and nintedanib in patients with non-small cell lung cancer and interstitial lung disease
    Yamaguchi, Teppei
    Shimizu, Junichi
    Shigematsu, Fumie
    Watanabe, Naohiro
    Hasegawa, Takaaki
    Horio, Yoshitsugu
    Inaba, Yoshitaka
    Fujiwara, Yutaka
    JOURNAL OF THORACIC DISEASE, 2024, 16 (05) : 3371 - 3380
  • [25] Non-small cell lung cancer (NSCLC) in elderly patients
    Batura-Gabryel, H.
    Brajer, B.
    LUNG CANCER, 2006, 52 : S19 - S19
  • [26] CHEMOTHERAPY IN NON-SMALL CELL LUNG-CANCER (NSCLC)
    KLASTERSKY, J
    EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1989, 25 (07): : 1035 - 1038
  • [27] The cost of non-small cell lung cancer (NSCLC) treatment
    Vergnenegre, A.
    ONCOLOGIE, 2012, 14 (05) : 310 - 315
  • [28] MicroRNA landscape in non-small cell lung cancer (NSCLC).
    Morgensztern, Daniel
    Devarakonda, Siddhartha H. K.
    Awh, Caroline
    Guebert, Kalin
    Maher, Christopher
    Maggi, Leonard B.
    Waqar, Saiama Naheed
    Carpenter, Danielle
    Robertson, Gordon
    Link, Daniel C.
    Govindan, Ramaswamy
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [29] The surgeon and the oncologist in non-small cell lung cancer (NSCLC)
    Sartori, F.
    Bortolotti, L.
    Marulli, G.
    Rizzardi, G.
    Favaretto, A.
    Zuin, A.
    Breda, C.
    Rea, F.
    ANNALS OF ONCOLOGY, 2006, 17 : V94 - V98
  • [30] Chemotherapy for advanced non-small cell lung cancer (NSCLC)
    Manegold, C
    LUNG CANCER, 2002, 38 : S47 - S50
12345